FindTrial
Sign In

Survival Outcomes of Adjuvant Taxanes, Platinum Plus Fluoropyrimidines versus Platinum and Fluoropyrimidines for Gastric Cancer Patients after D2 Gastrectomy

Survival Outcomes of Adjuvant Taxanes, Platinum Plus Fluoropyrimidines versus Platinum and Fluoropyrimidines for Gastric Cancer Patients after D2 Gastrectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053393
Enrollment
Unknown
Registered
2021-11-20
Start date
2021-11-20
Completion date
Unknown
Last updated
2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Taxanes,Platinum Plus Fluoropyrimidines group:No
Platinum Plus Fluoropyrimidines group:No

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
21 Years to 84 Years

Inclusion criteria

Inclusion criteria: 1. Patients with gastric cancer who received concurrent adjuvant chemotherapy after D2 radical resection; 2. Detailed postoperative pathological reports are available for staging; 3. Postoperative radiological assessment; 4. Receive at least one cycle of systemic adjuvant chemotherapy.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
disease-free survival;—

Secondary

MeasureTime frame
overall survival;—

Countries

China

Contacts

Public ContactMa Tai

The First Affiliated Hospital of Anhui Medical University

matai@ahmu.edu.cn+86 55162923615

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026